Gilead Sciences
GILD
$0.51 (-0.78%)
1D
1W
3M
1Y
5Y
ALL
Gilead Sciences, Inc. is a biopharmaceutical company that is focused on advancing medicines to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company's portfolio of products and pipeline of investigational drugs includes treatments for HIV/acquired immune deficiency syndrome (AIDS), COVID-19, liver diseases, hematology/oncology/cell therapy and other. Its products for HIV/AIDS patients include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada and Atripla. It offers Veklury to patients with COVID-19. The Company's products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Viread and Vosevi. Its products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy and Zydelig. Other products include Letairis, Ranexa and AmBisome. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. The Company operates in more than 335 countries worldwide.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Seeking Alpha • 1 day ago • GILD
Gilead Sciences: Disappointing Fundamentals And Sentiment, But Still BullishSeeking Alpha • 1 day ago • GILD
Unloved Gilead Due For Reversal On Flight-To-Safety Money FlowsBarrons • 4 days ago • GILD
Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.Seeking Alpha • 5 days ago • GILD
Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart InvestorsInvestorPlace • 6 days ago • GILD
3 Biotech Stocks to Buy Now: May 2024Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.